In order to proactively address areas of concern to the FDA and other regulators, All units within each pharmaceutical firm should review recent regulatory observations and proactively establish programs or systems to address the regulatory concerns.
FDA 483 Observations in the Laboratory. What went wrong? How can they be avoided? - Webinar By GlobalCompliancePanel
12 January 2011, Wilmington, United States
Introduction
Venue
Online Training Webinar
Online Training Webinar, 1000 N West Street | Suite 1200, Wilmington, 19801, United States
Useful links
Organised by
GlobalCompliancePanel
Contact information
Related events
Chemistry Teaching in Practice
9 January 2025 09:30-16:00, Oxford, United Kingdom
TAC 2025 - 60th Anniversary Conference
14 April 2025 09:00 - 16 April 2025 17:00, Guildford, United Kingdom
Top of the Bench Lancashire Local Section Heat
16 January 2025 10:00-15:30, Preston, United Kingdom
Redefining the Chemical Status Quo: Women Catalysts for Equality
11 February 2025 10:00-13:00, Abuja, Nigeria
Search
Advertisement
Spotlight
Explore
Membership
